EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy

被引:1
|
作者
Castano, Adam
Heitner, Stephen B. [1 ]
Masri, Ahmad [1 ]
Huda, Ahsan
Calambur, Veena
Bruno, Marianna
Schumacher, Jennifer
Emir, Birol
Isherwood, Catherine
Shah, Sanjiv j. [2 ,3 ]
机构
[1] Pfizer Inc, New York, NY USA
[2] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Amyloidosis Ctr, Portland, OR USA
[3] Northwestern Univ, Feinberg Sch Med, 633 N St Clair St,Suite 19-015, Chicago, IL 60611 USA
关键词
Wild-type transthyretin amyloidosis; cardiomyopathy; heart failure; machine learning; HEART-FAILURE;
D O I
10.1016/j.cardfail.2023.11.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), an increasingly recognized cause of heart failure (HF), often remains undiagnosed until later stages of the disease. Methods and Results: A previously developed machine learning algorithm was simpli fi ed to create a random forest model based on 11 selected phenotypes predictive of ATTRwt-CM to estimate ATTRwt-CM risk in hypothetical patient scenarios. Using U.S. medical claims datasets (IQVIA), International Classi fi cation of Diseases codes were extracted to identify a training cohort of patients with ATTRwt-CM (cases) or nonamyloid HF (controls). After assessment in a 20% test sample of the training cohort, model performance was validated in cohorts of patients with International Classi fi cation of Diseases codes for ATTRwt-CM or cardiac amyloidosis vs nonamyloid HF derived from medical claims (IQVIA) or electronic health records (Optum). The simpli fi ed model performed well in identifying patients with ATTRwt-CM vs nonamyloid HF in the test sample, with an accuracy of 74%, sensitivity of 77%, speci fi city of 72%, and area under the curve of 0.82; robust performance was also observed in the validation cohorts. Conclusions: This simpli fi ed machine learning model accurately estimated the empirical probability of ATTRwt-CM in administrative datasets, suggesting it may serve as an easily implementable tool for clinical assessment of patient risk for ATTRwt-CM in the clinical setting. Brief lay summary: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM for short) is a frequently overlooked cause of heart failure. Finding ATTRwt-CM early is important because the disease can worsen rapidly without treatment. Researchers developed a computer program that predicts the risk of ATTRwt-CM in patients with heart failure. In this study, the program was used to check for 11 medical conditions linked to ATTRwt-CM in the medical claims records of patients with heart failure. The program was 74% accurate in identifying ATTRwt-CM in patients with heart failure and was then used to develop an educational online tool for doctors (the wtATTR-CM estimATTR). ( J Cardiac Fail 2024;30:778 - 787 )
引用
收藏
页码:778 / 787
页数:10
相关论文
共 50 条
  • [41] Survival Benefit With Higher Dose Tafamidis in Patients With Hereditary and Wild-type Transthyretin Amyloid Cardiomyopathy
    Shah, Sanjiv J.
    Gundapaneni, Balarama
    Sultan, Marla B.
    Merlini, Giampaolo
    CIRCULATION, 2020, 142
  • [42] Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy
    Porcari, A.
    Razvi, Y.
    Masi, A.
    Patel, R.
    Ioannou, A.
    Rauf, M. U.
    Venneri, L.
    Martinez-Naharro, A.
    Merlo, M.
    Sinagra, G.
    Lachmann, H.
    Wechalekar, A.
    Hawkins, P. N.
    Fontana, M.
    Gillmore, J. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 356 - 356
  • [43] Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy
    Porcari, Aldostefano
    Razvi, Yousuf
    Masi, Ambra
    Patel, Rishi
    Ioannou, Adam
    Rauf, Muhammad U.
    Hutt, David F.
    Rowczenio, Dorota
    Gilbertson, Janet
    Martinez-Naharro, Ana
    Venneri, Lucia
    Whelan, Carol
    Lachmann, Helen
    Wechalekar, Ashutosh
    Quarta, Candida Cristina
    Merlo, Marco
    Sinagra, Gianfranco
    Hawkins, Philip N.
    Fontana, Marianna
    Gillmore, Julian D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (04) : 515 - 524
  • [44] Implementing clinical pathways to enable early diagnosis and treatment of wild-type transthyretin amyloid cardiomyopathy
    Muller, Steven A.
    Oerlemans, Marish I. F. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (06) : 854 - 856
  • [45] Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model (vol 29, pg 530, 2023)
    Bruno, M.
    Sheer, R.
    Reed, C.
    Schepart, A.
    Nair, R.
    Simmons, J. D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (07): : 769 - 769
  • [46] Right ventricular-dominant transthyretin deposition: an early stage or a rare phenotype of wild-type transthyretin amyloid cardiomyopathy?
    Hata, Satoshi
    Ota, Shingo
    Tanaka, Atsushi
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2023, 24 (06) : E99 - E99
  • [47] Prognostic Role of Cardiopulmonary Exercise Testing in Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Treated With Tafamidis
    Dalia, Tarun
    Acharya, Prakash
    Chan, Wan-chi
    Sauer, Andrew J.
    Weidling, Robert
    Fritzlen, John
    Goyal, Amandeep
    Miller, Dana
    Knipper, Elaine
    Porter, Charles B.
    Shah, Zubair
    JOURNAL OF CARDIAC FAILURE, 2021, 27 (11) : 1285 - 1289
  • [48] Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark
    Pilgaard, Trine
    Pedersen, Mikkel Hasse
    Poulsen, Steen Hvitfeldt
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1084 - 1091
  • [49] Assessment of Physical Performance in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Evaluated by Cardiopulmonary Exercise Testing
    Willixhofer, R.
    Rettl, R.
    Kronberger, C.
    Duca, F.
    Binder, C.
    Kammerlander, A.
    Kastner, J.
    Bergler-Klein, J.
    Badr-Eslam, R.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S479 - S479
  • [50] Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm
    Inomata, Takayuki
    Tahara, Nobuhiro
    Nakamura, Kazufumi
    Endo, Jin
    Ueda, Mitsuharu
    Ishii, Tomonori
    Kitano, Yoshinobu
    Koyama, Jun
    ESC HEART FAILURE, 2021, 8 (04): : 2647 - 2659